ORLANDO, Fla., May 19, 2013 /PRNewswire/ -- The non-surgical Stretta® procedure employing low power and low temperature radiofrequency (RF) energy is effective in control of gastroesophageal reflux disease (GERD), and eliminates or reduces the need for medication 10 years post-procedure, according to an independent, prospective long-term assessment presented today at the Digestive Disease Week (DDW) meeting May 18-21, 2013 in Orlando, Florida.
"The sustained improvement in GERD-HRQL scores and patient satisfaction, coupled with the potential for protection against esophageal cancer validate the long-term usefulness of this safe, clinically effective and economically effective endoscopic procedure," said principal investigator Mark Noar , M.D., Director, Endoscopic Microsurgery Associates, Maryland. "Of the 99 study participants with refractory GERD followed for 10 years, 41 percent no longer required the PPI medications they were taking pre-Stretta."
Approximately 20 percent of Americans suffer the symptoms of GERD – frequent heartburn or acid reflux, burning sensation in the chest or throat or regurgitation – at least once a week, according to the National Institutes of Health.
In some adults with GERD, atypical symptoms may present, such as dry cough, asthma, or trouble swallowing rather than, or in addition to heartburn.
Some 12 million Americans who do not respond to conservative GERD management – dietary changes or drug treatment – could potentially benefit from the Stretta procedure, including those with the atypical manifestations.
10-Year Post-Stretta Data Conclusions:
|SOURCE Mederi Therapeutics|
Copyright©2012 PR Newswire.
All rights reserved